Analysis of tetanus toxin peptide/DR recognition by human T cell receptors reconstituted into a murine T cell hybridoma - PubMed (original) (raw)
. 1993 Dec;23(12):3057-65.
doi: 10.1002/eji.1830231203.
Affiliations
- PMID: 8258318
- DOI: 10.1002/eji.1830231203
Analysis of tetanus toxin peptide/DR recognition by human T cell receptors reconstituted into a murine T cell hybridoma
U Blank et al. Eur J Immunol. 1993 Dec.
Abstract
We have previously reported that human T cell receptors (TcR) selected in the class II-restricted (HLA-DRB1*1302) response to a tetanus toxin peptide (tt830-843) frequently used the V beta 2 germ-line segment which paired with several V alpha segments and that the putative CDR3 of both alpha and beta chains showed remarkable heterogeneity. To analyze the structural basis for recognition of the tt830-843/DR complex, five of these TcR were reconstituted into a murine T cell hybridoma, 58 alpha- beta-, by expressing the human alpha and beta variable regions joined to the mouse alpha and beta constant regions, respectively. The chimeric TcR, expressing the same V beta germ-line segment (V beta 2), two expressing V alpha 21.1, two V alpha 17.1 and one V alpha 8.1 were shown to have the expected antigen specificity and DR restriction. Two lines of evidence suggested that the putative CDR3, although not conserved in these TcR, played a key role in recognition. First, two TcR with identical V germ-line segments but distinct CDR3 showed large difference in their capacity to react with the ligand. Second, interchanging the alpha and beta chains from tt830-843/DR1302-specific TcR which differed in their CDR3 sequences invariably led to loss of recognition. We also asked whether germ-line V alpha 17.1 could functionally replace V alpha 21.1, as they appear to be related in their primary sequence. However, as in the case of CDR3 exchanges, V alpha replacement abrogated TcR reactivity. Taken together, these data underline the fine interdependence of the structural components of the TcR binding site in defining a given specificity. Four of the TcR studied displaying promiscuous recognition were also tested against different DR alleles and site-directed mutants. The results of these experiments suggested that, in spite of their structural heterogeneity, anti-tt830-843 TcR may have a similar orientation with respect to the peptide/DR complex. The reconstitution system described herein should represent a valuable tool for detailed studies of human TcR specificity.
Similar articles
- Strong similarities in antigen fine specificity among DRB1* 1302-restricted tetanus toxin tt830-843-specific TCRs in spite of highly heterogeneous CDR3.
Boitel B, Blank U, Mège D, Corradin G, Sidney J, Sette A, Acuto O. Boitel B, et al. J Immunol. 1995 Apr 1;154(7):3245-55. J Immunol. 1995. PMID: 7534793 - Human TCR-gamma/delta alloreactive response to HLA-DR molecules. Comparison with response of TCR-alpha/beta.
Flament C, Benmerah A, Bonneville M, Triebel F, Mami-Chouaib F. Flament C, et al. J Immunol. 1994 Oct 1;153(7):2890-904. J Immunol. 1994. PMID: 8089476 - Thymic repertoire selection by superantigens: presentation by human and mouse MHC molecules.
Simpson E, Takacs K, Altmann DM. Simpson E, et al. Thymus. 1994;23(1):1-13. Thymus. 1994. PMID: 7863543 Review. - The structural basis of T cell activation by superantigens.
Li H, Llera A, Malchiodi EL, Mariuzza RA. Li H, et al. Annu Rev Immunol. 1999;17:435-66. doi: 10.1146/annurev.immunol.17.1.435. Annu Rev Immunol. 1999. PMID: 10358765 Review.
Cited by
- TCR modifications that enhance chain pairing in gene-modified T cells can augment cross-reactivity and alleviate CD8 dependence.
Spear TT, Foley KC, Garrett-Mayer E, Nishimura MI. Spear TT, et al. J Leukoc Biol. 2018 May;103(5):973-983. doi: 10.1002/JLB.5A0817-314R. Epub 2018 Jan 19. J Leukoc Biol. 2018. PMID: 29350789 Free PMC article. - Single-cell analysis of glandular T cell receptors in Sjögren's syndrome.
Joachims ML, Leehan KM, Lawrence C, Pelikan RC, Moore JS, Pan Z, Rasmussen A, Radfar L, Lewis DM, Grundahl KM, Kelly JA, Wiley GB, Shugay M, Chudakov DM, Lessard CJ, Stone DU, Scofield RH, Montgomery CG, Sivils KL, Thompson LF, Farris AD. Joachims ML, et al. JCI Insight. 2016 Jun 2;1(8):e85609. doi: 10.1172/jci.insight.85609. JCI Insight. 2016. PMID: 27358913 Free PMC article. - Multiple sclerosis: Molecular mimicry of an antimyelin HLA class I restricted T-cell receptor.
Rühl G, Niedl AG, Patronov A, Siewert K, Pinkert S, Kalemanov M, Friese MA, Attfield KE, Antes I, Hohlfeld R, Dornmair K. Rühl G, et al. Neurol Neuroimmunol Neuroinflamm. 2016 May 17;3(4):e241. doi: 10.1212/NXI.0000000000000241. eCollection 2016 Aug. Neurol Neuroimmunol Neuroinflamm. 2016. PMID: 27231714 Free PMC article. - Strategies to genetically engineer T cells for cancer immunotherapy.
Spear TT, Nagato K, Nishimura MI. Spear TT, et al. Cancer Immunol Immunother. 2016 Jun;65(6):631-49. doi: 10.1007/s00262-016-1842-5. Epub 2016 May 2. Cancer Immunol Immunother. 2016. PMID: 27138532 Free PMC article. Review. - The fully synthetic MAG-Tn3 therapeutic vaccine containing the tetanus toxoid-derived TT830-844 universal epitope provides anti-tumor immunity.
Laubreton D, Bay S, Sedlik C, Artaud C, Ganneau C, Dériaud E, Viel S, Puaux AL, Amigorena S, Gérard C, Lo-Man R, Leclerc C. Laubreton D, et al. Cancer Immunol Immunother. 2016 Mar;65(3):315-25. doi: 10.1007/s00262-016-1802-0. Epub 2016 Feb 4. Cancer Immunol Immunother. 2016. PMID: 26847142 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials